KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Non-Current Assets: 2009-2025

Historic Non-Current Assets for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Sep 2025 value amounting to $27.1 billion.

  • Teva Pharmaceutical Industries' Non-Current Assets fell 7.89% to $27.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $27.1 billion, marking a year-over-year decrease of 7.89%. This contributed to the annual value of $26.8 billion for FY2024, which is 13.62% down from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported Non-Current Assets of $27.1 billion as of Q3 2025, which was down 1.42% from $27.5 billion recorded in Q2 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Non-Current Assets registered a high of $36.6 billion during Q1 2021, and its lowest value of $26.8 billion during Q4 2024.
  • For the 3-year period, Teva Pharmaceutical Industries' Non-Current Assets averaged around $29.3 billion, with its median value being $29.7 billion (2024).
  • Data for Teva Pharmaceutical Industries' Non-Current Assets shows a maximum YoY decreased of 13.83% (in 2021) over the last 5 years.
  • Teva Pharmaceutical Industries' Non-Current Assets (Quarterly) stood at $35.1 billion in 2021, then declined by 8.93% to $32.0 billion in 2022, then declined by 3.02% to $31.0 billion in 2023, then dropped by 13.62% to $26.8 billion in 2024, then decreased by 7.89% to $27.1 billion in 2025.
  • Its last three reported values are $27.1 billion in Q3 2025, $27.5 billion for Q2 2025, and $26.9 billion during Q1 2025.